Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world bevacizumab-based combination regimens in solid tumors
ChiCTR2500105527Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Nonhematologic neoplasms, bronchial carcinoma, colorectal cancer (CRC) and 1 more, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: drug-related adverse events (AEs), abnormal laboratory test values and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
Nonhematologic neoplasmsbronchial carcinomacolorectal cancer (CRC)liver cancer
Beyond the preview
Go deeper on ChiCTR2500105527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105527.